Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Other Non-Current Assets (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Other Non-Current Assets for 5 consecutive years, with $287000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 24.24% to $287000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $287000.0 through Dec 2025, up 24.24% year-over-year, with the annual reading at $287000.0 for FY2025, 24.24% up from the prior year.
  • Other Non-Current Assets hit $287000.0 in Q4 2025 for Krystal Biotech, down from $333000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $402000.0 in Q1 2023 to a low of $62000.0 in Q3 2021.
  • Historically, Other Non-Current Assets has averaged $211300.0 across 5 years, with a median of $204000.0 in 2022.
  • Biggest five-year swings in Other Non-Current Assets: surged 337.84% in 2022 and later tumbled 55.79% in 2024.
  • Year by year, Other Non-Current Assets stood at $74000.0 in 2021, then skyrocketed by 337.84% to $324000.0 in 2022, then fell by 18.83% to $263000.0 in 2023, then fell by 12.17% to $231000.0 in 2024, then rose by 24.24% to $287000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for KRYS at $287000.0 in Q4 2025, $333000.0 in Q3 2025, and $197000.0 in Q2 2025.